September 7, 2023

Procyrion Secures New Medicare Payment Codes Applicable to its Aortix™ Percutaneous Mechanical Circulatory Support Technology

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support (pMCS) technology.

Read More
ALL
Press Releases
Articles
Publications
Awards

Press Release

Aortix™ Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Procyrion, Inc. announced today that use of its Aortix™ percutaneous mechanical circulatory support (pMCS) device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure (ADHF) and worsening renal function, which is known as cardiorenal syndrome (CRS).

March 21, 2023
  • Press Releases

Press Release

Procyrion Announces Successful First-in-Human Cases with Aortix™ Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery

Procyrion announces successful first-in-human cases with Aortix™ pump to prevent acute kidney injury in patients undergoing cardiac surgery. Study adds to the growing body of data for the Aortix™ pump, which will be featured in a presentation at the Technology and Heart Failure Therapeutics conference in March.

February 22, 2023
  • Press Releases

Press Release

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

November 2, 2021
  • Press Releases

Press Release

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

May 25, 2021
  • Press Releases

Press Release

Procyrion Names Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing

Av Edidin, Ph.D., brings > 25 years of in depth experience as a global medical device leader, and will help Procyrion prepare for upcoming clinical studies of the Aortix™ system for the treatment of in-hospital cardiorenal patients.

August 6, 2019
  • Press Releases

Press Release

Procyrion Receives FDA Breakthrough Device Designation for Aortix™ System

• Resting the heart while perfusing the kidneys, Aortix aims to treat heart failure symptoms by disrupting the cardiorenal syndrome cycle • Potential to offer significant advantages for patients with acute decompensated heart failure (ADHF) who also have worsening renal function

July 30, 2019
  • Press Releases

Press Release

Procyrion Raises $30 Million Series D to Support Clinical Trials of its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients

The $30M Series D funding, led by a new investor, Bluebird Ventures, will support the Aortix's pilot study through the submission of an FDA IDE application for its pivotal trial.

July 9, 2019
  • Press Releases
Older Posts
The Aortix™ device is currently in the research and development phase and is not available for sale in any country.
Caution: Investigational Device. Limited by Federal Law to Investigational Use.

Links

HomeClinical TrialsOverviewTeamNewsCareersReferencesDisclaimer & Terms of UseContact

LATEST NEWS

September 2023
Press Release
Procyrion Secures New Medicare Payment Codes Applicable to its Aortix™ Percutaneous Mechanical Circulatory Support Technology
March 2023
Press Release
Aortix™ Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function
February 2023
Press Release
Procyrion Announces Successful First-in-Human Cases with Aortix™ Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery

ABOUT US

Procyrion is a team of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists.

Our dedicated team is working to address the unmet clinical needs of heart failure patients through the development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device.

Copyright © 2021 Procyrion, Inc.
Disclaimer & Terms of Use
Aortix™ is for investigational use only and is not for sale in the United States.